Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pens and vouchers: can small rewards boost participation in blood cancer research?

NCT ID NCT01831635

Knowledge-focused Sponsor: Queen's University, Belfast Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 11, 2026 · Last updated Sep 11, 2026

Summary

Researchers want to learn what causes myeloproliferative neoplasms, a group of rare blood cancers. They are testing whether small incentives like pens, trolley tokens, or a £10 reimbursement encourage more people to join a case-control study. The trial includes about 100 patients with these cancers and 200 healthy controls. The goal is to find the best ways to recruit participants for a larger UK-wide study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Small incentives such as branded pens, trolley tokens, and a £10 reimbursement
What this could lead to
If successful, this could help researchers design larger studies that uncover what causes myeloproliferative neoplasms, potentially guiding prevention.
What could go wrong
This is an early, small study focused on recruitment methods, not on finding causes or treatments. It may not improve participation enough to justify a larger study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

234 people

The number who actually took part.

Started

Apr 2013

Finished

Jun 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Hematology clinic Primary Care clinic Non-blood relatives/ friends of cases

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Myeloproliferative neoplasm cases Inclusion criteria: * Clinical diagnosis of polycythemia vera, essential thrombocythaemia or primary myelofibrosis based on the WHO diagnostic criteria. * Aged 18 years or older. Exclusion Criteria: * younger than 18 years old. * where the clinician/General Practitioner (GP) does not provide consent. * incapable of giving informed consent. * physically or cognitively incapable of completing the questionnaire. * too ill to participate General Practice Controls Inclusion Criteria: * Randomly selected, frequency matched to the distribution of cases by 5-year age band, geographic location (Belfast and Southampton) and gender. * Aged 18 years or older. Exclusion Criteria: * younger than 18 years old. * where the clinician/GP does not provide consent. * incapable of giving informed consent. * physically or cognitively incapable of completing the questionnaire. * too ill to participate. Relative/Friend Controls Inclusion Criteria: * Non-blood relative/friend of a case participating in the study. * Aged 18 years or older. Exclusion Criteria: * younger than 18 years old. * where the clinician/GP does not provide consent. * incapable of giving informed consent. * physically or cognitively incapable of completing the questionnaire. * too ill to participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Essential thrombocythemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera essential thrombocythemia primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Essential thrombocythemia Polycythemia vera Primary myelofibrosis

Contacts and locations

Locations

  • Belfast Health And Social Care Trust

    Belfast, Northern Ireland, BT12 6BJ, United Kingdom

  • Queen's University Belfast

    Belfast, Northern Ireland, BT389EX, United Kingdom

  • University Hospitals Southampton NHS Foundation Trust

    Southampton, England, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.